Designed to Help Industry Deliver Safe and Proper Repairs to Today's Increasingly Complex Vehicles
A good stay-at-work program can offer many benefits to employees and employers, but establishing a successful plan can sometimes be a challenge. To help make this process easier, I'm joined by experts Kevin Ufier and Linda Mastropaolo who will offer tips on how to develop a successful program.
First Script saw a decrease in opioid utilization across our retail and mail-order programs in 2018. In 2017, opioids made up 29.7% of total prescriptions, dropping to 26.9% in 2018, and representing a 2.8% decrease in utilization year over year.
A good stay-at-work program can offer many benefits to employees and employers, but establishing a successful plan can sometimes be a challenge. To help make this process easier, I'm joined by Genex experts Kevin Ufier and Linda Mastropaolo who will offer tips on how to develop a successful program.
Momentum in battling the opioid crisis continues. As more states enact opioid prescribing limits, the federal government proposes new legislation, while new studies look at the impact of opioid laws and medical marijuana on lessening opioid abuse.
As the U.S. looks for ways to stem the opioid crisis, one major strategy that has emerged is the use of naloxone to counteract opioid overdoses. The FDA’s recent approval of the generic form of Narcan®, which is the first generic formulation for naloxone nasal spray, provides another avenue to reverse the impact of the opioid crisis.
In 2018 Coventry’s pharmacy benefit management solution, First Script®, saw a 7.8% decrease in average MED per prescription for its retail and mail-order channels. This was the largest decrease in the last 5 years across First Script’s retail and mail-order programs. In addition, there was a reduction in the percentage of opioid scripts with greater than or equal to 90 MED. To better understand why this is important let’s answer a few questions.